CV Safety Role of SUs in the Era of CV Safety Concern in T2DM


Dr Vijay Viswanathan, Chennai    31 January 2018

  1. nondiabetic counterparts.
  2. Guidance for industry - A therapy should demonstrate that it will not result in an unacceptable increase in: CV mortality; myocardial infarction (MI) and stroke; hospitalization for acute coronary syndrome, urgent revascularization procedures; other endpoints. CV safety of modern vs. older SUs: Modern SUs like glimepiride do not inhibit mitochondrial KATP channels in the heart; hence, the protective mechanism of ischemic preconditioning (IPC) is preserved with glimepiride; older SUs inhibit mitochondrial KATP, which further inhibits IPC. The use of 2nd and 3rd generation SUs in patients with type 2 diabetes is not associated with increased CV risk irrespective of comparator or background medication.
  3. SUs as an add-on to metformin have been considered safe in terms of overall and CV mortality. In a recent pragmatic trial, incidence of CV events was similar with SUs and pioglitazone as add-on treatments to metformin. New SUs (glimepiride/gliclazide) may be associated with a lower risk of MI than old SUs (glibenclamide). Modern SUs have fewer early complications and lower mortality than older SUs. Newer SUs, especially glimepiride, may be preferred in patients with underlying CAD.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.